TG Therapeutics Inc. [NASDAQ: TGTX] gained 3.46% or 0.37 points to close at $11.05 with a heavy trading volume of 5810511 shares. The company report on August 1, 2023 at 7:15 AM that TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results.
Second quarter 2023 BRIUMVI® net sales of $16 million in the United States, representing 100% quarter over quarter growth; total net revenue of approximately $24 million since launch.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Over 1,200 BRIUMVI prescriptions since launch from 340+ healthcare providers at 225+ centers across the U.S.
It opened the trading session at $10.66, the shares rose to $11.28 and dropped to $10.5299, the range by which the price of stock traded the whole day. The daily chart for TGTX points out that the company has recorded -36.60% loss over the past six months. However, it is still -127.37% lower than its most recent low trading price.
If we look at the average trading volume of 4.78M shares, TGTX reached to a volume of 5810511 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about TG Therapeutics Inc. [TGTX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TGTX shares is $28.94 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TGTX stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for TG Therapeutics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 02, 2023.
The Average True Range (ATR) for TG Therapeutics Inc. is set at 0.80, with the Price to Sales ratio for TGTX stock in the period of the last 12 months amounting to 68.31. The Price to Book ratio for the last quarter was 38.10, with the Price to Cash per share for the same quarter was set at 0.97.
Trading performance analysis for TGTX stock
TG Therapeutics Inc. [TGTX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.64. With this latest performance, TGTX shares gained by 9.41% in over the last four-week period, additionally sinking by -36.60% over the last 6 months – not to mention a rise of 62.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TGTX stock in for the last two-week period is set at 38.44, with the RSI for the last a single of trading hit 49.36, and the three-weeks RSI is set at 35.56 for TG Therapeutics Inc. [TGTX]. The present Moving Average for the last 50 days of trading for this stock 16.20, while it was recorded at 10.68 for the last single week of trading, and 17.56 for the last 200 days.
TG Therapeutics Inc. [TGTX]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and TG Therapeutics Inc. [TGTX] shares currently have an operating margin of -6924.20 and a Gross Margin at +71.99. TG Therapeutics Inc.’s Net Margin is presently recorded at -7121.54.
Return on Total Capital for TGTX is now -84.24, given the latest momentum, and Return on Invested Capital for the company is -87.40. Return on Equity for this stock declined to -134.13, with Return on Assets sitting at -69.20. When it comes to the capital structure of this company, TG Therapeutics Inc. [TGTX] has a Total Debt to Total Equity ratio set at 141.77. Additionally, TGTX Total Debt to Total Capital is recorded at 58.64, with Total Debt to Total Assets ending up at 42.91. Long-Term Debt to Equity for the company is recorded at 139.07, with the Long-Term Debt to Total Capital now at 57.52.
Reflecting on the efficiency of the workforce at the company, TG Therapeutics Inc. [TGTX] managed to generate an average of -$877,588 per employee. Receivables Turnover for the company is 4.01 with a Total Asset Turnover recorded at a value of 0.01.TG Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.50 and a Current Ratio set at 2.90.
An analysis of Institutional ownership at TG Therapeutics Inc. [TGTX]
The top three institutional holders of TGTX stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in TGTX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in TGTX stock with ownership which is approximately 5.7381%.
